4-(6-CHLORO-2,4-DIOXO-1,2,3,4-TETRAHYDROPYRIMIDIN-5-YL) BUTYL PHOSPHATE

Identification

Generic Name
4-(6-CHLORO-2,4-DIOXO-1,2,3,4-TETRAHYDROPYRIMIDIN-5-YL) BUTYL PHOSPHATE
DrugBank Accession Number
DB08016
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
Weight
Average: 298.617
Monoisotopic: 298.012150345
Chemical Formula
C8H12ClN2O6P
Synonyms
Not Available

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
U6,7-dimethyl-8-ribityllumazine synthaseNot AvailableMycobacterium tuberculosis
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as halopyrimidines. These are aromatic compounds containing a halogen atom linked to a pyrimidine ring. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazines
Sub Class
Pyrimidines and pyrimidine derivatives
Direct Parent
Halopyrimidines
Alternative Parents
Monoalkyl phosphates / Pyrimidones / Aryl chlorides / Hydropyrimidines / Vinylogous halides / Heteroaromatic compounds / Vinylogous amides / Lactams / Ureas / Azacyclic compounds
show 6 more
Substituents
Alkyl phosphate / Aromatic heteromonocyclic compound / Aryl chloride / Aryl halide / Azacycle / Halopyrimidine / Heteroaromatic compound / Hydrocarbon derivative / Hydropyrimidine / Lactam
show 15 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
organochlorine compound, pyrimidone, monoalkyl phosphate (CHEBI:47505)
Affected organisms
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
Not Available
InChI Key
DAUATIBSDSXXHA-UHFFFAOYSA-N
InChI
InChI=1S/C8H12ClN2O6P/c9-6-5(7(12)11-8(13)10-6)3-1-2-4-17-18(14,15)16/h1-4H2,(H2,14,15,16)(H2,10,11,12,13)
IUPAC Name
[4-(6-chloro-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)butoxy]phosphonic acid
SMILES
OP(O)(=O)OCCCCC1=C(Cl)NC(=O)NC1=O

References

General References
Not Available
PubChem Compound
11987823
PubChem Substance
99444487
ChemSpider
10160296
ChEMBL
CHEMBL500082
ZINC
ZINC000040976115
PDBe Ligand
JCL
PDB Entries
2c97

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.39 mg/mLALOGPS
logP-0.58ALOGPS
logP-0.017Chemaxon
logS-2.3ALOGPS
pKa (Strongest Acidic)1.81Chemaxon
pKa (Strongest Basic)-5Chemaxon
Physiological Charge-2Chemaxon
Hydrogen Acceptor Count5Chemaxon
Hydrogen Donor Count4Chemaxon
Polar Surface Area124.96 Å2Chemaxon
Rotatable Bond Count6Chemaxon
Refractivity71.78 m3·mol-1Chemaxon
Polarizability25.21 Å3Chemaxon
Number of Rings1Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption-0.9564
Blood Brain Barrier+0.7647
Caco-2 permeable-0.6606
P-glycoprotein substrateNon-substrate0.6575
P-glycoprotein inhibitor INon-inhibitor0.9012
P-glycoprotein inhibitor IINon-inhibitor1.0
Renal organic cation transporterNon-inhibitor0.9011
CYP450 2C9 substrateNon-substrate0.6808
CYP450 2D6 substrateNon-substrate0.8218
CYP450 3A4 substrateNon-substrate0.5671
CYP450 1A2 substrateNon-inhibitor0.7172
CYP450 2C9 inhibitorNon-inhibitor0.8189
CYP450 2D6 inhibitorNon-inhibitor0.8857
CYP450 2C19 inhibitorNon-inhibitor0.733
CYP450 3A4 inhibitorNon-inhibitor0.9196
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.894
Ames testNon AMES toxic0.6632
CarcinogenicityNon-carcinogens0.8936
BiodegradationNot ready biodegradable0.9185
Rat acute toxicity2.4768 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9044
hERG inhibition (predictor II)Non-inhibitor0.8113
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-0002-9610000000-d72acaa22bc0340b37f2
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0002-0090000000-ed7cb4929c329e49d7bb
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-000t-9150000000-a8b3f7c70f14b7ce4c47
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0uxs-0190000000-5ce7ac4a2b71003fd2aa
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-001i-9000000000-cd4c4db5d3afafa2eef2
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-003r-9000000000-d2c6d045ac43a123afd1
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0ktb-2930000000-1b55936a4d30a20122da
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-144.47629
predicted
DeepCCS 1.0 (2019)
[M+H]+146.84514
predicted
DeepCCS 1.0 (2019)
[M+Na]+153.30325
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Mycobacterium tuberculosis
Pharmacological action
Unknown
General Function
Catalyzes the formation of 6,7-dimethyl-8-ribityllumazine by condensation of 5-amino-6-(D-ribitylamino)uracil with 3,4-dihydroxy-2-butanone 4-phosphate. This is the penultimate step in the biosynthesis of riboflavin.
Specific Function
6,7-dimethyl-8-ribityllumazine synthase activity
Gene Name
ribH
Uniprot ID
P9WHE9
Uniprot Name
6,7-dimethyl-8-ribityllumazine synthase
Molecular Weight
16370.415 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]

Drug created at September 15, 2010 21:27 / Updated at June 12, 2020 16:52